Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986253 in Myelodysplastic Syndromes
NCT05148234Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adakitug in myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Started Nov 2022; status: terminated.
02
Drugs
adakitug
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05148234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148234.